ERBB2 and breast cancer: The proportion of both TNBC and HER-2 overexpression breast cancer was much smaller in the non-PABC patients (17.4% in non-PABC vs. 30.1% in PABC, P < 0.001; 8.0% in non-PABC vs. 15.8% in PABC, P < 0.001, respectively) (Fig. 1).